Background Cocaine use disorder (CUD) has significant consequences and there remain
no FDA-approved pharmacotherapies. Ondansetron is an indirect dopaminergic modulator …

Background In a previous study, ondansetron, a serotonin 5‐HT3 receptor antagonist,
reduced drinking intensity (drinks/drinking day [DPDD]) among European‐ancestry (EA) …

Bipolar disorder is associated with high rates of alcohol use disorder. However, little is
known about the treatment of this dual diagnosis population. Previous studies suggest that …

Background: Pharmacogenetics uses genetic variation to predict individual differences in
response to medications and holds much promise to improve treatment of addictive …

Background Disulfiram may be efficacious for treating cocaine dependence or abuse,
possibly through inhibiting dopamine β-hydroxylase (DβH). Consequently, this randomized …

Background Alcohol use disorder (AUD) is among the leading causes of morbidity and
mortality worldwide, and over 95 million people live with alcohol dependence globally. The …

Background Cocaine use contines to be a significant public health problem world‐wide.
However, despite substantial research efforts, no pharmacotherapies are approved for the …

Objective Prior research demonstrated that the δ-opioid receptor (OPRD1) rs678849 variant
influences opioid use in African Americans treated with methadone. We examined whether …

Background Cocaine use disorder (CUD) is a significant public health issue for which there
is no Food and Drug Administration-approved pharmacotherapy. Depressive disorders are …

Prior studies have demonstrated inefficacy among dopamine receptor antagonists for
treating cocaine dependence. An alternative approach would be to investigate the ability of …